Implansense Closes $3.5M Seed Round to Advance Cardiac Telemetry Analytics

Today we're sharing that Implansense has closed a $3.5 million seed round. The funding will be used to accelerate platform development, deepen integrations with the remote monitoring services and EHR systems that EP clinics depend on, and expand the clinical informatics team that sits at the core of what we're building.

We started Implansense in 2024 with a specific observation: cardiac device clinics managing high-volume remote monitoring programs were drowning in undifferentiated transmission queues, and the vendor-specific monitoring platforms — as capable as they are at capturing and transmitting device data — weren't designed to solve the cross-vendor clinical triage problem that device clinic teams face every morning. That observation led us to build the Alert Triage Engine, the Remote Follow-Up Scheduler, and the Clinical Timeline that form the core of the Implansense platform.

What the funding reflects

The seed round reflects what we've heard consistently from EP program directors, device clinic nurse managers, and cardiology IT directors over the past 18 months. The problem we're addressing is real, it's present at virtually every high-volume device clinic, and it doesn't have a clear solution in the current tool landscape.

Medtronic CareLink, Abbott Merlin.net, Boston Scientific LATITUDE, and Biotronik Home Monitoring are the authoritative data sources for their respective devices. They are not, and were not designed to be, cross-vendor clinical workflow tools. The gap between "device data arriving from multiple manufacturer systems" and "clinician having a prioritized, actionable queue" is the problem we're solving. Our early clinical partners have described that gap clearly, and the interest from investors reflects confidence that it's a problem worth building for.

What we're building next

The near-term development roadmap focuses on three areas where we've heard the most consistent feedback from our early clinical partners.

Integration breadth and depth. Our current integrations cover the major remote monitoring services. The most immediate expansion need is deeper structured data ingestion — moving beyond alert-level transmission summaries to the full episode electrogram data and parameter trend history that clinical review requires. This is a non-trivial data engineering problem given the format heterogeneity across manufacturer platforms, and it's where a meaningful portion of the seed capital is going.

EHR connectivity. The friction of having device telemetry data in one system and the clinical chart in another is a daily operational problem for device clinic teams. Building out the HL7 FHIR R4 integration paths — particularly the SMART on FHIR app launch pattern that surfaces device context within the EHR encounter — is a development priority for the coming months. EHR integration for remote monitoring requires getting the data model right before it requires getting the user interface right.

Follow-up scheduling maturity. The Remote Follow-Up Scheduler's core capability — urgency-weighted scheduling queues for ICD, pacemaker, and ILR patients — needs to extend into tighter coordination with the clinic's actual scheduling system. The gap between "this patient is surfaced in the follow-up queue" and "this patient has a scheduled appointment or documented callback" is where patients fall through. Closing that gap is a workflow design and integration challenge, not primarily a clinical analytics one.

The team and the Philadelphia ecosystem

We're building in Philadelphia because this is where we started and because Philadelphia's cardiac care ecosystem — Penn Medicine, Jefferson Health, Temple Health, a dense network of community cardiology programs and EP practices — gives us proximity to the clinical teams we're building for. The Philadelphia medtech ecosystem, historically strong in cardiovascular medicine and cardiac device development, is a genuine context for what we're doing, not a marketing framing.

The team we're expanding with this funding includes clinical informatics expertise, cardiology workflow knowledge, and software engineering depth focused on healthcare data integration. We're not building a generic healthcare analytics platform. We're building specifically for the EP clinic and cardiac device monitoring context. That specificity requires people who understand the clinical domain deeply — the difference between a pacemaker lead impedance trend and an ICD high-voltage coil impedance excursion, the clinical weight of CRT pacing percentage in a documented HF patient, the false-positive rate characteristics of ILR episode detection. Those distinctions shape every feature decision.

A note on what we're not changing

Raising seed funding doesn't change the core architecture decisions that define what Implansense is and isn't. We're not building a device manufacturer replacement. We're not building a clinical decision support system that makes diagnostic recommendations. We're not building a standalone EHR. The platform will continue to position itself as the analytics and workflow layer between the data sources your clinic already uses — the manufacturer monitoring services, the EHR — and the clinical team that needs to act on that data.

The device clinic nurse manager who opens Implansense at 7:30 AM should see a queue sorted by clinical urgency, with the events that need her attention today surfaced at the top, and a clear path from each alert to the next clinical action. That hasn't changed, and it won't. The platform overview describes the three pillars — Alert Triage Engine, Remote Follow-Up Scheduler, Clinical Timeline — in their current form. The seed funding accelerates execution on that roadmap; it doesn't redirect it.

If you're managing a device clinic and want to talk about what this looks like in your workflow, we'd like to hear from you. The problems we're building for are specific enough that the most useful conversations are the ones where we're looking at actual transmission volumes, actual device panel composition, and actual pain points — not a generic demo script.

Thank you to our early clinical partners

We don't name customers at this stage, and we won't. But the device clinic teams who spent time with us during the development process — walking us through their queues, explaining the heuristics they've developed to manage alert volume, and telling us plainly when early versions of the triage logic were getting the urgency scoring wrong — shaped the platform in ways that wouldn't have happened in isolation from clinical practice. That feedback loop is the most important thing we've built, and it's not going away as we scale.

The structural problem in cardiac device clinic workflow — too much data, too little prioritization, no cross-vendor triage layer — has been acknowledged broadly in the EP clinical community. The 2023 update to the HRS Expert Consensus guidance on remote monitoring for cardiovascular implantable electronic devices reinforces the clinical standard-of-care expectation that significant events receive timely attention. Meeting that standard at the transmission volumes high-volume programs manage requires tooling that current clinic workflows don't provide. That's the gap we're closing.

We're grateful to the investors who saw the problem clearly enough to fund this stage of development, and to the clinical community that has engaged seriously with what we're building. The work continues.